Akorn and Fidia Farmaceutici to develop ANDA products
Akorn, based in Illinois, US, is to develop four Abbreviated New Drug Application (ANDA) drug products with Fidia Farmaceutici, a privately-held pharmaceutical company based in Padova, Italy.
Akorn, based in Illinois, US, is to develop four Abbreviated New Drug Application (ANDA) drug products with Fidia Farmaceutici, a privately-held pharmaceutical company based in Padova, Italy.
The four products include one ointment and one cream for topical application, and two tablet formulations used in the immuno compromised anti-viral market. The combined current market size of the four drugs is approximately US$1bn.
Fidia develops and markets healthcare products, mainly based on sodium hyaluronate (HA) and its derivatives. It will be responsible for product development and manufacturing of all four products including clinical development of the two tablet formulations.
Akorn, which markets and distributes hospital and ophthalmic pharmaceuticals, will be responsible for the clinical development of the ointment and cream formulations along with sales and marketing. It will make milestone development fee payments to Fidia and have exclusive rights to market these four drugs in the US and Canada.